Stockreport

Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution

Matinas Biopharma Holdings, Inc.  (MTNB) 
NASDAQ:AMEX Investor Relations: ir.matinasbiopharma.com
PDF A total of 19 patients with serious/life-threatening invasive fungal infections have been enrolled, including aspergillosis, mucormycosis, fusarium, candidiasis, cryptoc [Read more]